Credit Suisse Starts Achaogen (AKAO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Cowen Starts Achaogen (AKAO) at Outperform
April 8, 2014 8:08 AM EDTCowen initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $12.89 yesterday.
... MoreWilliam Blair Starts Achaogen (AKAO) at Outperform
April 7, 2014 4:26 PM EDTWilliam Blair initiated coverage on Achaogen (NASDAQ: AKAO) with an Outperform rating.
For an analyst ratings summary and ratings history on Achaogen click here. For more ratings news on Achaogen click here.
Shares of Achaogen closed at $14.15 yesterday.
... MoreNeedham & Company Starts Achaogen (AKAO) at Buy
April 7, 2014 7:17 AM EDTNeedham & Company initiates coverage on Achaogen (NASDAQ: AKAO) with a Buy rating and a price target of $21.00.
Analyst Alan Car comments, "Lead drug plazomicin is under development for the treatment of infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). A Phase 3 trial... More
